TocilizumabNeutropenia following off-label use: case report

被引：0

|

作者：

机构：

来源：

Reactions Weekly | 2021年 / 1853卷 / 1期

关键词：

D O I：

10.1007/s40278-021-95312-3

中图分类号：

学科分类号：

摘要：

引用

收藏

页码：446 / 446

相关论文

共 50 条

[1] Prednisone/tocilizumabNeutropenia following off-label use and rebound effect in the form of recurrence of scleritis: case report
[J]. Reactions Weekly, 2020, 1817 (1) : 282 - 282
[2] AmantadineConstipation following off-label use: case report
[J]. Reactions Weekly, 2019, 1760 (1) : 20 - 20
[3] PembrolizumabHyperthyroidism following off-label use: case report
[J]. Reactions Weekly, 2017, 1643 (1) : 239 - 239
[4] OmalizumabFever following off-label use: case report
[J]. Reactions Weekly, 2019, 1773 (1) : 265 - 265
[5] RituximabNeutropenia following an off-label use: case report
[J]. Reactions Weekly, 2018, 1706 (1) : 442 - 442
[6] PralatrexateStomatitis following off-label use: case report
[J]. Reactions Weekly, 2021, 1842 (1) : 309 - 309
[7] DenosumabHypocalcaemia following off-label use: case report
[J]. Reactions Weekly, 2020, 1808 (1) : 108 - 108
[8] DaratumumabHypogammaglobulinemia following off-label use: case report
[J]. Reactions Weekly, 2019, 1744 (1) : 111 - 111
[9] GlibenclamideHypoglycaemia following off-label use: case report
[J]. Reactions Weekly, 2021, 1857 (1) : 162 - 162
[10] NivolumabPsoriasis following an off-label use: case report
[J]. Reactions Weekly, 2018, 1717 (1) : 214 - 214

← 1 2 3 4 5 →